Subscribe To

Price Alert Latest News Economic Calendar News

RVLP / RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25 th Annual Global Investment Conference in New York City as follows: Read More

Demo Live Account See Partner Details

Content Topics

Pharmaceuticals

Present

Wainwright

25th

Annual

Global

Investment

Conference

Stock

RVLP

Posted: Aug 23 2023, 16:05

Author Name: GlobeNewsWire

RVLP News

By InvestorPlace
October 6, 2023

Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?

RVL Pharmaceuticals (NASDAQ: RVLP ) stock is climbing higher on Friday despite a lack of news from the specialty pharmaceutical company. There aren't

By GlobeNewsWire
August 23, 2023

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutic

By Seeking Alpha
December 30, 2022

RVL Pharmaceuticals: A First 'Look'

Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only

By Seeking Alpha
November 10, 2022

RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Rel

By Zacks Investment Research
August 11, 2022

RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the num

By Seeking Alpha
August 11, 2022

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q2 2022 Results - Earnings Call Transcript

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Brian Markiso

By Seeking Alpha
May 12, 2022

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q1 2022 Results - Earnings Call Transcript

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relation

By Seeking Alpha
March 30, 2022

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q4 2021 Results - Earnings Call Transcript

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.